Biotech entity
clinical-trial is the sole category represented across all 1 tracked stories. Doxorubicin is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Van Ness rotationplasty, all published on September 13, 2026.
Last mentioned: 6d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
clinical-trial is the sole category represented across all 1 tracked stories. Doxorubicin is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Van Ness rotationplasty, all published on September 13, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Van Ness rotationplasty. Shared-story counts are live from our verified record — not editorial picks.
Mileah's treatment — doxorubicin-based chemotherapy followed by rotationplasty — reflects an osteosarcoma standard of care that has barely changed in decades, highlighting a rare pediatric tumor with high unmet need.
Source: perthnow.com.au · bluemountainsgazette.com.au
Van Ness rotationplasty is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
